Compare REGN & ORLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | ORLY |
|---|---|---|
| Founded | 1988 | 1957 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto & Home Supply Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8B | 72.0B |
| IPO Year | 1995 | 1996 |
| Metric | REGN | ORLY |
|---|---|---|
| Price | $796.95 | $92.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 17 |
| Target Price | ★ $830.16 | $111.59 |
| AVG Volume (30 Days) | 764.3K | ★ 7.3M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | ★ 8.19 | N/A |
| EPS | ★ 18.95 | 1.58 |
| Revenue | $5,872,227,000.00 | ★ $17,781,992,000.00 |
| Revenue This Year | $12.45 | $8.67 |
| Revenue Next Year | $10.13 | $6.22 |
| P/E Ratio | ★ $42.06 | $58.59 |
| Revenue Growth | ★ 20.82 | 6.42 |
| 52 Week Low | $541.00 | $82.59 |
| 52 Week High | $821.11 | $108.72 |
| Indicator | REGN | ORLY |
|---|---|---|
| Relative Strength Index (RSI) | 77.83 | 56.15 |
| Support Level | $738.17 | $89.59 |
| Resistance Level | $818.06 | $94.04 |
| Average True Range (ATR) | 21.79 | 2.38 |
| MACD | 7.78 | 0.36 |
| Stochastic Oscillator | 91.45 | 74.91 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
O'Reilly is an aftermarket automotive parts retailer in the United States and Mexico with more than $16 billion in annual sales. The company operates over 6,000 domestic stores and serves both the do-it-yourself (about 50% of sales) and professional (47% of sales) end markets. O'Reilly differentiates itself by providing quality service to its customers throughout the entirety of the vehicle diagnosis and purchasing process. Furthermore, the firm boasts an impressive hub-and-spoke distribution network designed to provide its localized store base with ample aftermarket part availability across a variety of vehicle makes and models.